Fosun Intl 1H Revenue Keeps Growing, Debt Ratio Reduces to 50.2%

August 28, 2024 11:34 PM AEST | By Cision

Google News:

Fosun Intl 1H Revenue Keeps Growing, Debt Ratio Reduces to 50.2% — Image source: Kalkine Media

Recent News

ASX200 Stocks Eye Calm Rebound as Energy, Uranium Sectors Show Diverge...

Greatland Resources Set for ASX200 Exposure with Strong Demand Ahead o...

Element 25 Advances Butcherbird Expansion with A$50M NAIF Backing; Set...

Trump's G7 Exit Disrupts Key ASX200 Diplomacy as Albanese's Meeting Sc...

HONG KONG, Aug. 28, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656) announced its interim results for the six months ended 30 June 2024. During the Reporting Period, the Group's revenue continued to grow, reaching RMB97.84 billion; industrial operation profit maintained growth, reaching RMB3.47 billion. The four core subsidiaries, namely Yuyuan, Fosun Pharma, Fosun Insurance Portugal, and Fosun Tourism Group, achieved a total revenue of RMB72.17 billion, maintaining year-on-year growth and accounting for 74% of the Group's total revenue.

As of the end of the Reporting Period, the Group's adjusted total debt-to-capital ratio was 50.2%, maintaining a downward trend since 2020. Cash and bank balances and term deposits reached RMB109.55 billion, representing an increase of RMB17.1 billion compared to the end of 2023. International rating agency S&P fully recognized the effectiveness of Fosun's financial strategy and affirmed its rating outlook as "stable".

In the 17 years since its listing, Fosun has accumulatively paid out HK$25.6 billion in dividends, with the dividend payout ratio gradually increasing to over 20% in the past five years. As of the end of the Reporting Period, adjusted NAV was HK$17.4 per share.

High-quality global business has become a new growth driver of Fosun. As of the end of the Reporting Period, Fosun has established industrial presence in over 35 countries and regions around the world, the Group's overseas revenue reached RMB45.87 billion in the first half of 2024, representing a year-on-year increase of 4%, and accounting for 47% of total revenue.

In the first half of 2024, Fosun's investment in technology innovation reached RMB3.5 billion. It achieved groundbreaking progress in innovative drugs R&D, 4 products with a total of 9 indications were approved for marketing; 4 products with a total of 9 indications had entered the pre-launch approval stage/ key clinical stage; and 9 products (by indication) have been approved to conduct clinical trials.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.